Business
Amid plans to induct Noel’s son, Tata trust cancels meet – The Times of India
MUMBAI: The Sir Ratan Tata Trust (SRTT) cancelled its Saturday board meeting, which was expected to consider the induction of chairman Noel Tata’s son, Neville Tata, as a trustee. In contrast, board meetings of Sir Dorabji Tata Trust (SDTT) and Tata Education and Development Trust (TEDT) proceeded as scheduled.The cancellation suggests that Neville’s appointment may have been pushed back to give trustees more time for discussions – since appointing a trustee requires unanimous approval. No new date for the SRTT meeting has been notified. An email query to Tata Trusts on the cancellation of the board meeting received no response. Sir Ratan Tata Trust (SRTT), Sir Dorabji Tata Trust (SDTT), and Tata Education and Development Trust (TEDT) have several trustees in common. Except for Jehangir HC Jehangir and Jimmy Tata, the other SRTT trustees — Noel, Venu Srinivasan, Vijay Singh and Darius Khambata — also serve on SDTT’s board and participated in its meeting on Saturday, people familiar with the matter said. Jimmy, Noel’s older half-brother, usually does not attend SRTT meetings.Saturday’s development comes amid unresolved issues from the last round of inductions in Nov 2025 when the inductions of Neville and former Titan MD Bhaskar Bhat were approved by SDTT but failed to secure approval at SRTT. SDTT, together with SRTT, controls India’s largest conglomerate, the Tata Group.At the Nov 11, 2025 SDTT meeting, Khambata proposed Neville’s appointment, while Noel proposed Bhat, as TOI reported in its Nov 12 edition. Neither name was on the formal board agenda. All trustees of SDTT approved the appointments (Srinivasan did not attend the meeting as his term had expired). Later, at SRTT’s meeting on the same day, both proposals were put off for consideration at a later date.Srinivasan, who participated in the SRTT meeting, reportedly expressed reservations, stating that these proposals were not on the agenda and that such matters should not be raised under “any other items for discussion.” While items not listed on the agenda can be introduced with the chairman’s permission, Srinivasan suggested they be considered at the next board meeting, according to a person familiar with the discussion.This time, Neville’s appointment was formally listed on the SRTT agenda but the meeting was cancelled. Bhat’s name did not appear on Saturday’s agenda. Neville participated at the SDTT meeting on Saturday, marking his first formal role at the flagship foundation.
Business
Anthropic officially designated a supply chain risk by Pentagon
The supply chain risk designation of the artificial intelligence firm is a first for a US company.
Source link
Business
FDA official calls UniQure’s gene therapy a ‘failed’ treatment for Huntington’s disease
Thomas Fuller | SOPA Images | Lightrocket | Getty Images
UniQure needs to run another study to prove that its gene therapy “actually helps people with Huntington’s disease,” a senior U.S. Food and Drug Administration official said on a call with reporters Thursday.
The official, who requested anonymity before discussing sensitive information, confirmed the agency has asked the company to run a placebo controlled trial of its treatment, which is administered directly into the brain. UniQure has said that type of study isn’t ethical because it would require putting people under general anesthesia for hours, a characterization the official disputed.
“So what is really going on? UniQure is the latest company to make a failed therapy for Huntington’s patients,” the official said. “They likely acknowledge or understand at some deep level that their trial failed years ago, and instead of doing the right thing and running the correct clinical study, UniQure is performing a distorted or manipulated comparison in the mind of FDA.”
The comments mark the latest development in a messy public spat between UniQure and the FDA, and as the agency comes under fire for a number of recent drug approval application rejections, including some where companies have accused it of going back on previous guidance. FDA Commissioner Marty Makary in an interview with CNBC’s Becky Quick last week seemingly criticized UniQure’s gene therapy for Huntington’s disease. Makary didn’t name UniQure but described its treatment.
UniQure then accused the FDA of reversing its stance that the company’s clinical trial data would be sufficient to seek approval. UniQure’s study used an outside database to measure how patients with Huntington’s disease might decline without treatment, known as an external control. UniQure has said it wouldn’t be feasible to run a true randomized, double-blind placebo-controlled study, considered the gold standard, because it wouldn’t be ethical to make people undergo a sham hours-long brain surgery.
The FDA official said the agency “never agreed to accept this distorted comparison” and the FDA “never makes such assurances.” Instead, the “FDA will always say, ‘Well, we have to see the data when we get it.'”
UniQure didn’t immediately comment.
The company’s stock rose more than 10% on Thursday and has fallen 58% this year as of Thursday afternoon.
Business
US mortgage rates rise to 6% after three-week slide as oil-driven bond yields climb – The Times of India
The average long-term US mortgage rate edged higher this week, ending a three-week decline as bond yields rose amid oil-price pressures linked to the war with Iran.The benchmark 30-year fixed mortgage rate increased to 6% from 5.98% last week, mortgage buyer Freddie Mac said on Thursday. A year ago, the average rate stood at 6.63%, AP reported.The modest uptick breaks a three-week slide in borrowing costs, with mortgage rates having hovered close to the 6% mark for most of this year. Last week’s average had marked the first time the rate dipped below 6% since September 2022, reaching its lowest level in nearly three and a half years.Mortgage rates are influenced by several factors, including the Federal Reserve’s interest-rate policy, investor expectations about inflation and economic growth, and movements in the bond market.They typically track the direction of the 10-year US Treasury yield, which lenders use as a benchmark for pricing home loans.The 10-year Treasury yield rose to 4.14% at midday Thursday, up from around 4% a week earlier.Treasury yields have moved higher in recent days as rising oil prices added fresh inflation concerns, potentially complicating the Federal Reserve’s plans to cut interest rates.
-
Politics1 week agoWhat are Iran’s ballistic missile capabilities?
-
Business7 days agoIndia Us Trade Deal: Fresh look at India-US trade deal? May be ‘rebalanced’ if circumstances change, says Piyush Goyal – The Times of India
-
Business1 week agoAttock Cement’s acquisition approved | The Express Tribune
-
Politics1 week agoUS arrests ex-Air Force pilot for ‘training’ Chinese military
-
Fashion1 week agoPolicy easing drives Argentina’s garment import surge in 2025
-
Business6 days agoGreggs to reveal trading amid pressure from cost of living and weight loss drugs
-
Sports6 days agoLPGA legend shares her feelings about US women’s Olympic wins: ‘Gets me really emotional’
-
Fashion7 days agoTexwin Spinning showcasing premium cotton yarn range at VIATT 2026
